<DOC>
	<DOCNO>NCT00871923</DOCNO>
	<brief_summary>The goal clinical research study learn whether Tarceva ( erlotinib hydrochloride ) , give addition whole brain radiation therapy , good treat brain metastases patient Non-Small Cell Lung Cancer ( NSCLC ) .</brief_summary>
	<brief_title>Tarceva With Whole Brain Radiation Therapy - Brain Mets From Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>The Study Drugs : Erlotinib hydrochloride design block activity protein find surface many tumor cell may control tumor growth survival . This may stop tumor grow . Study Drug Administration : If find eligible take part study , take study drug Days 1-6 receive radiation therapy . You take 1 pill day least 1 hour 2 hour eat . You take study drug receive radiation therapy . You continue take study drug daily radiation therapy complete long study doctor think necessary . You record time day take study drug calendar provide . You bring calendar study visit . During time take study drug , must tell research staff change drug take . If feel problem study drug start radiation therapy , must tell study doctor right away . Radiation Therapy : After Day 6 take study drug , begin radiation therapy . You receive radiation therapy 1 time day ( Monday Fridays ) total 14 day . Once week radiation therapy : - You physical exam . - You complete quality life questionnaire ( last week visit ) - You complete mini-mental status exam ( last week visit ) - You ask change drug may take - You ask feel side effect may - You blood draw ( 1/2 teaspoon ) lab test necessary . One month Radiation therapy follow : - You follow visit 1 month radiation therapy complete . The study doctor decide continue take study drug follow-up visit . The following test procedure perform : - You physical exam . - You MRI CT brain . - Your vital sign record . - You complete quality life questionnaire . - You complete mini-mental status exam . - You ask change drug may take . - You ask feel side effect may . - You blood draw ( 1/2 teaspoon ) lab test necessary . Follow-up Visits ( While Tarceva ) : If , end-of-study visit , doctor decides continue take study drug , follow-up visit research nurse 1 time month . At visit , follow test procedure perform : ( If unable return MDACC , visit conduct telephone arrangement make mail study Tarceva medication . ) - Your medical history review . - You receive 30-day supply study drug . - You bring study drug calendar nurse review . - You ask feel side effect may . - You also ask change drug may take . - Blood ( 1/2 teaspoon ) may draw routine test . The following test procedure perform every 3 month : - You physical exam . - You MRI CT brain - Your vital sign record . Follow visit ( Discontinuation Study Drug ) : You follow visit research nurse 1 month last dose study drug , follow perform : ( If unable return MDACC , visit conduct telephone arrangement make study Tarceva medication medication diary return mail . ) - Your medical history review . - You ask feel side effect may . - You return study drug calendar remain Tarceva tablet research nurse . - You also ask change drug may take - Your vital sign record . The following test procedure perform every 3 month ( Tarceva ) first 2 year every 6 month thereafter : - You physical exam . - Your medical history review . - You MRI CT brain - If unable return follow visit due physical condition , contact phone . Duration Study Treatment : You remain study long study doctor think benefit study drug . You take study treatment early disease get bad , experience intolerable side effect , doctor think longer best interest continue receive treatment study . This investigational study . Erlotinib hydrochloride FDA approve commercially available . It FDA approve treat NSCLC spread brain . Up 20 patient take part study . All enrol MD Anderson .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Brain Neoplasms</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>1 . Histological confirmation nonsmall cell lung cancer 2 . Patients treat past stereotactic radiosurgery , stereotactic radiotherapy , GliaSite surgical resection allow enroll study 3 . A diagnostic contrastenhanced MRI CT scan must perform , demonstrate brain metastasis 4 . Age 1870 5 . Patients must KPS &gt; /= 70 6 . Patients treat treatment related protocol within 30 day prior study entry participation study 7 . No uncontrolled symptomatic major medical illness psychiatric impairment , Alzheimer 's schizophrenia 8 . Screening Clinical Laboratory Values : ANC &gt; 1500/ul , Platelets &gt; 80,000/ul , baseline AST and/or ALT within normal limit ( within 30 day start protocol treatment ) 9 . All woman childbearing potential ( A woman childbearing potential sexually mature woman undergone hysterectomy naturally postmenopausal least 24 consecutive month [ i.e. , menses time precede 24 consecutive month ] ) male participant must practice effective contraception ( abstinence , oral , injectable , implantable hormonal contraceptive ; tubal ligation ; intrauterine device ; barrier contraceptive spermicide ; vasectomized partner ) throughout study . 10 . Continued # 10 : All woman childbearing potential must negative serum pregnancy test practice birth control study . 11 . Patients must provide verbal write informed consent participate study . 1 . Prior cranial radiation therapy , stereotactic radiosurgery , Stereotactic Radiotherapy GliaSite . 2 . Patients know Acquired Immune Deficiency ( AIDS ) , regimens tyrosine kinase inhibitor may pose safety risk relate excess toxicity interference antiviral effectiveness 3 . Women pregnant lactating , due possible adverse effect develop fetus infant due study drug 4 . Patients active connective tissue disorder , lupus scleroderma</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Non-small cell lung cancer</keyword>
	<keyword>NSCLC</keyword>
	<keyword>Brain Metastases</keyword>
	<keyword>Brain Cancer</keyword>
	<keyword>Lung Cancer</keyword>
	<keyword>Tarceva</keyword>
	<keyword>Erlotinib Hydrochloride</keyword>
	<keyword>OSI-774</keyword>
	<keyword>Radiation Therapy</keyword>
	<keyword>Whole Brain Radiation Therapy</keyword>
	<keyword>WBRT</keyword>
</DOC>